Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351239 | 0.85 | CYP3A4 (0.61) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL10334048 | 0.84 | HSP90AA1 (0.62) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL10810029 | 0.81 | HSP90AA1 (0.62) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL9661865 | 0.81 | HSP90AA1 (0.58) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL10333452 | 0.80 | CYP3A4 (0.64) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL9874872 | 0.79 | KMT2A (0.48) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL9547001 | 0.79 | KMT2A (0.51) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL10845813 | 0.78 | KMT2A (0.53) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL9661013 | 0.78 | KMT2A (0.86) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL10521049 | 0.78 | CYP3A4 (0.54) | KMT2ACYP3A4CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | claimed |
| EP-0250198-B1 | BIS-AZOLYL COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-28 | — | — | EP | claimed |
| EP-0250198-A2 | Bis-azolyl compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-23 | — | — | EP | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| WO-2003082336-A1 | FEMALE BIRTH CONTROL METHOD | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002083146-A1 | MULTIPLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083241-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083239-A1 | AROMATASE INHIBITORS FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083240-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| US-4933357-A | 1,3-diazolyl-2-phenylalkyl-2-propanol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-12 | — | — | US | disclosed |
| EP-0250198-B1 | BIS-AZOLYL COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-28 | — | — | EP | disclosed |
| EP-0250198-A2 | Bis-azolyl compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | KMT2A 1177/4885CYP3A4 32/4885CYP19A1 1/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | KMT2A 491/4885CYP3A4 532/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.